Non-clinical statistics – Quo vadis?

Lea A.I. Vaas1, Tina Lang1, Hannes-Friedrich Ulbrich1, Bernd-Wolfgang Igl2

1 Bayer AG, Research & Development, Pharmaceuticals, Research & Pre-Clinical Statistics

2 Boehringer Ingelheim Pharma GmbH & Co. KG, Global Biostatistics & Data Sciences

Statistics and data science have been embraced as partners in many fields in addition to the classical clinical development. In the pharmaceutical research & pre-clinical development however, it still finds itself in a “nice-to-have”-corner.

Obviously, with less interest of regulatory authorities the tendency for investing into statistical support also decreases notably. From a business perspective the diversion of resources along these lines absolutely makes sense.

With ongoing changes in the field of non- and pre-clinical research towards 3R (reduce, replace, refine), activities accelerating the phasing out of animal testing and technical breakthroughs resulting in advanced organ-on-a-chip or organoids the whole field is moving.

This interactive round should serve as a starting point for getting an overview of ongoing changes, underlying mechanisms and existing and emerging opportunities to position statistics and data sciences more prominently and influential in the process of research and development.